Nuvation Bio Inc.
A biopharmaceutical company that develops targeted drugs for hard-to-treat cancers, Nuvation Bio makes the oral lung-cancer medicine IBTROZI (taletrectinib), approved by U.S. regulators in 2025 for patients whose non-small cell lung cancer carries a specific ROS1 gene change. It was founded in 2018 by Dr. David Hung, the same doctor behind the prostate-cancer drugmaker Medivation. The name blends "Nu-" with "-vation," a nod to innovation and to Hung's earlier Medivation success.
Granted 58.65M · Bought 1.00M
Granted 500.0K
Granted 6.17M · Bought 777.9K
Granted 10.08M · Bought 854.5K
Sold 500.0K
Sold 7.26M
Bought 5.71M · Sold 208.1K
Granted 1.93M · Sold 56.4K
Granted 659.9K
Bought 250.0K
Bought 225.0K
Bought 172.2K
Granted 125.0K · Bought 10.0K · Sold 125.0K
Granted 299.8K · Bought 50.0K · Sold 299.8K
Bought 50.0K
Granted 50.8K
Granted 290.0K · Sold 290.0K
Granted 55.0K
Granted 25.0K
Granted 25.0K
Granted 35.0K
Granted 200.0K · Sold 200.0K
Granted 47.7K · Bought 7.3K · Sold 47.7K
Bought 5.0K
Granted 569.1K · Sold 569.1K
Granted 304.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Hung DavidPRESIDENT AND CEO, Director, 10% owner · 6 transactions | — | 59.28Mas of Jun 2025 | 58.65M | 1.00M | — |
| Doig Michelle +6 co-filersDirector, 10% owner · 2 transactions | — | 28.21Mas of Feb 2021 | 500.0K | — | — |
| Cui XiangminDirector · 10 transactions | — | 25.95Mas of Sep 2024 | 6.17M | 777.9K | — |
| Nodelman Oleg +6 co-filers10% owner, Director · 15 transactions | — | 23.85Mas of Apr 2021 | 10.08M | 854.5K | — |
| Omega Fund IV GP, L.P. +2 co-filers10% owner · 1 transaction | — | 22.96Mas of Dec 2021 | — | — | 500.0K |
| Omega Fund V GP Manager, Ltd. +2 co-filers10% owner · 7 transactions | — | 20.46Mas of Apr 2022 | — | — | 7.26M |
| Nodelman Oleg +5 co-filersDirector · 9 transactions | — | 12.67Mas of Sep 2023 | — | 5.71M | 208.1K |
| Wang Junyuan JerryCEO, ANHEART THERAPEUTICS LTD., Director · 5 transactions | — | 6.11Mas of Nov 2024 | 1.93M | — | 56.4K |
| Welch Daniel GDirector · 2 transactions | — | 659.9Kas of May 2024 | 659.9K | — | — |
| Falberg Kathryn EDirector · 4 transactions | — | 250.0Kas of Dec 2022 | — | 250.0K | — |
| Mashal RobertDirector · 5 transactions | — | 225.0K | — | 225.0K | — |
| Blickenstaff Kim DDirector · 1 transaction | — | 172.2Kas of Jun 2024 | — | 172.2K | — |
| Markel StacyCHIEF PEOPLE OFFICER · 4 transactions | — | 157.6K | 125.0K | 10.0K | 125.0K |
| Wentworth KerryCHIEF REGULATORY OFFICER · 9 transactions | — | 116.0K | 299.8K | 50.0K | 299.8K |
| Sjogren ColleenChief Commercial Officer · 1 transaction | — | 84.0K | — | 50.0K | — |
| Makunje MosesSEE REMARKS · 1 transaction | — | 68.1K | 50.8K | — | — |
| Liu DongfangCHIEF MEDICAL OFFICER · 16 transactions | — | 68.0K | 290.0K | — | 290.0K |
| Hasnain FaheemDirector · 2 transactions | — | 55.0Kas of Feb 2021 | 55.0K | — | — |
| Bradbury DanielDirector · 1 transaction | — | 25.0Kas of Feb 2021 | 25.0K | — | — |
| Cooper Graham KDirector · 1 transaction | — | 25.0Kas of Feb 2021 | 25.0K | — | — |
| Sharp ShaliniDirector · 2 transactions | — | 25.0Kas of Feb 2021 | 35.0K | — | — |
| Hanley David C.CHIEF TECHNICAL OPERATIONS · 2 transactions | — | 24.0K | 200.0K | — | 200.0K |
| Sauvage PhilippeChief Financial Officer · 4 transactions | — | 12.7K | 47.7K | 7.3K | 47.7K |
| Bazemore Robert BDirector · 1 transaction | — | 5.0Kas of Mar 2021 | — | 5.0K | — |
| Hattersley GaryCHIEF SCIENTIFIC OFFICER · 8 transactions | — | 0 | 569.1K | — | 569.1K |
| Vernon W AnthonyDirector · 2 transactions | — | 0as of Feb 2021 | 304.1K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -442.9K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.